CA2207095A1 - System and method for distinguishing between vf/vt and bradycardia or asystole - Google Patents
System and method for distinguishing between vf/vt and bradycardia or asystoleInfo
- Publication number
- CA2207095A1 CA2207095A1 CA002207095A CA2207095A CA2207095A1 CA 2207095 A1 CA2207095 A1 CA 2207095A1 CA 002207095 A CA002207095 A CA 002207095A CA 2207095 A CA2207095 A CA 2207095A CA 2207095 A1 CA2207095 A1 CA 2207095A1
- Authority
- CA
- Canada
- Prior art keywords
- electrode
- shock
- patient
- arrhythmia
- pace
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3621—Heart stimulators for treating or preventing abnormally high heart rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/37—Monitoring; Protecting
- A61N1/371—Capture, i.e. successful stimulation
- A61N1/3712—Auto-capture, i.e. automatic adjustment of the stimulation threshold
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
- A61N1/3962—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion in combination with another heart therapy
- A61N1/39622—Pacing therapy
Abstract
A system and method for more reliably detecting and treating arrhythmias such as ventricular fibrillation and tachycardia are provided. The system reacts to the detection of VF/VT by first looking for one or more sensed R waves to confirm arrhythmia. If the arrhythmia is confirmed, an appropriate shock is delivered directly. However, if the arrhytmia is not confirmed following a timed out confirmation duration, a pace pulse is delivered, following which the system looks to see if the pace pulse has resulted in capture of the patient's ventricle. Capture is determined by examining sensed far field signals that correlate with the delivered pace pulse. In a preferred embodiment the far field signals are sensed between aventricular fibrillation coil and a second electrode, the second electrode suitably being either an SCV electrode or the surface of the implanted defibrillator unit. If capture is determined, delivery of a shock is aborted, and the patient may be further treated with pacing therapy. If capture is not found, this indicates that the arrhythmia remains, even though not sensed during the confirmation duration, and shock therapy is applied directly.
Description
CA 0220709~ 1997-06-0~
SYSTEM AND METHOD FOR DISTINGUISHING BETWEEN
VF/VT AND BRADYCARDIA OR ASYSTOLE
BACKGROUND OF THE INVENTION
This invention relates to a system and method for defibrillation and/or cardioversion and, more particularly, for safely determining whether or not a detected arrhythmia has been sustained, and for avoiding delivering of an inappropriate shock when in fact arrhythmia has not been sustained and the patient has marked bradycardia or asystole.
The implantable cardioverter defibrillator (ICD) device has been shown to be effective in termin~ting episodes of ventricular fibrillation (VF) and ventricular tachycardia (VT). This capacity for detecting and termin~ting potentially lethal ~lhyllllllias such as VF/VT has been further combined with the pacemaker function, the combined unit being referred to as a PCD (pacemaker/cardioverter/
defibrillator) type device, such as made by Medtronic, Inc., the assignee of this invention. The capability of this device has been further enhanced by the development of leads for providing transvenous ventricular defibrillation. See, for example, U.S. Patents Nos. 4,932,407 and 5,174,288, disclosing lead systems providing transvenous ventricular defibrillation and cardioversion electrodes.
Likewise, subcutaneous defibrillation leads may be used. The PCD or ICD type device, together with the improved leads, make it possible to provide relativelyefficient systems for termin~ting VT or VF.
A rem~ining problem with such systems for dealing with such dangerous arrhythmias is the potential for delivering an inappropliate shock. Inparticular, this invention addresses the problem where an arrhythmia such as VT or VF has been accurately sensed but has not been sustained. In such a situation, the detection of VT or VF results in the system being primed to deliver a shock. If,however, the patient exhibits either marked bradycardia or asystole when the device seeks confirm~tion of the previously detected allhyLlllllia, the lack of a sensed signal can be taken as confirm~tion of an underlying arrhythmia, resulting in an CA 0220709~ 1997-06-0~
p4350 ina~plopliate shock. The total number of inapl~ropl;ate shocks varies according to the literature, but remains significant enough to be regarded as a major challenge. In order to deal with this, ICD and PCD type devices have incorporated a variety ofreconfirm~tion algorithms, which are aimed at confirming the underlying arrhythmia after it has been detected, thereby reducing the number of inapplopliate shocks. Of course, the confirm~tion, or reconfirm~tion algorithm must take into account that failure to deliver a shock when a potentially lethal arrhythmia persists cannot be accepted; the arrhythmia confirrn~tion needs to be substantially 100 percent.
As an example of the above, in a typical PCD type device, there is a confirm~tion period following detection of, for example, a condition of fibrillation.
This confirrn~tion period serves two purposes. First, an attempt is made to deliver shock therapy synchronously with a patient heartbeat, when a sustained arrhythmia is sensed. For this reason, the system may look for one or two R waves that are consistent with the arrhythmia, and deliver a synchronous shock. However, if a predetermined confirm~tion period expires without any sensed signal, then a shock is delivered asychronously at the end of such period. This could likely be the correct result, where the absence of a sensed R wave is reflective of an underlying fibrillation or other arrhythmia. However, the time out of the confirm~tion period can also result from the patient having reverted to marked bradycardia or asystole after a non-sustained arrhythmia. It is clear that it is desirable to distinguish such a marked bradycardia or asystole, i.e., a non-sustained arrhythmia, from an undersensed real arrhythmia (VF/VT). The safe differentiation between a bradycardia episode and aVF/VT episode is desirable in order to provide delivery of a more appropriate pacing therapy instead of an inappropriate shock.
There thus is presented a significant need for improving the confirm~tion routine of a PCD or ICD type device, so as to avoid shock delivery during the confirm:~tion period in the event of a bradycardia condition (e.g., bradycardia or asystole) after a non-sustained arrhythmia, without sacrificing the sensitivity of arrhythmia detection and following therapy. It is also important, in either case, to deliver the most approp~;ate and most beneficial therapy without delay:
CA 0220709~ 1997-06-0~
in the case of bradycardia or asystole after a non-sustained arrhythmia, this isappropriate anti-bradycardia pacing, while in the case of the ventricular arrhythmia this constitutes prompt defibrillation or cardioversion therapy.
SUMMARY OF THE INVENTION
In accordance with the above need in the art, there is provided a system and method for detecting cardiac arrhythmias such as ventricular fibrillation ortachycardia, the system having the capability following such a detection for accurately distinguishing between a sustained arrhythmia requiring shock therapy and a non-sustained arrhythmia which is replaced by brady conditions of the sort for which only 1~ pacing therapy is desired. The system includes a PCD type unit and a suitable electrode system such as an endocardial lead with defib and pacing electrodes. The system continually senses cardiac signals and detects from such sensed signals an occurrence of VT/VF. Following this, the system enters a confirm~tion sequence where it seeks to deliver a shock in the event that sustained VF or VT is confirmed.
The confirm~tion sequence lasts for at least a predetermined brady interval, and if arrhythmia is not positively confirmed, or a normal sinus rhythm is not detected, a pace pulse is delivered at the time out of the confirm~tion interval. The system looks to determine whether the delivered pace pulse has captured the heart, preferably by ex~mining any signal sensed at the defibrillation far field electrodes, which sensed signal is indicative of heart capture. If capture is sensed within a predetermined interval following the pace pulse, then the system continues in a pacer mode, e.g., VVI pacing. However, if capture is not sensed, this verifies that the underlyingarrhythmia has been sustained and a shock is delivered at the time out of the predetermined interval following delivery of the pace pulse. The capture detection feature is "fail-safe" with respect to reacting to a dangerous therapy, since failure to detect capture results in delivery of a shock.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is an illustration of a PCD type system according to the present invention.
. . CA 02207095 1997-06-05 Fig. 2A is a simple timing diagram illustrating the operation of a PCD
type device embodying the present invention.
Figs. 2B and 2C are timing diagrams illustrating specific arrangements of the confinn~tion period and follow-up capture period in accordance with this invention.
Fig.3 is a block, functional diagram of a PCD type device adapted to carry out the co~ tion and capture fe~L~LLes of the present invention.
Fig. 4 is a flow diagram of the logic illustrating the method of the present invention for an episode of ventricular fibrillation.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Refemng now to Fig. 1, there are illustrated a defibrillator 10 and a lead 16, m~kin~ up the PCD type system of this invention. The lead shown is illustrative, it being noted that other specific forms of leads are within the scope of this invention. See, for example, the above-referenced U.S. Patents Nos. 4,932,407 and 5,174,288, as well as 5,261,400 . The - lead as illustrated has, located adjacent the distal end, an e~t~n~l~kle helix electrode 26 and a ring electrode 24, the helix electrode being mounted retractably within aninsulative head 28. Electrodes 24 and 26 are utilized for bipolar cardiac pacing and for sensing ventricular depol~ri7~tions. While electrodes 24, 26 may be used forbipolar pacing and sensing, electrode 26 may be used in conjunction with a surface of device can 10, which surface acts as a common or indirre;lellt electrode in what is termed unipolar operation. The lead also carries a coil electrode 20, sometimes referred to as the RV coil, for delivering defibrillation andlor cardioversion pulses.
Electrode 20 is positioned on the lead so that when the distal tip is at the apex of the ventricle, coil 20 is positioned in the right ventricle. Lead 16 may also carry,optionally, an SCV coil 30, positioned in the subclavian vein, which can be used for R
wave sensing and/or applying cardioversion pulses. Lead 16 carries respective concentric coil conductors, separated from one another by al~propl;ate means such as tubular insulative sheaths and running the length of the lead for m~kin~ electrical CA 0220709~ 1997-06-0 connection between the PCD device 10 and respective ones of electrodes 20, 24, 26 and 30.
An implantable PCD type device, or defibrillator 10, is shown in combination with the lead, with the lead connector assembly 14 being inserted into the connector block 12 of the device 10. A specific example of a defibrillation pulse generator which may be used in conjunction with the present lead, is disclosed in U.S.
Patent No. 4,953,551. Other PCD type units can be used; reference is made to U.S.
Patents 5,163,427 and 5,188,105 as disclosing illustrative forms of apparatus for delivering cardioversion and defibrillation pulses. As used herein, the term "PCD
type" device refers to any device which can apply both pacing therapy and shock therapy for controlling allhyll~ ias.
Referring now to Fig. 2A, there is shown a simple timing diagram, which illustrates the timing sequence and the primary operations of the present invention. As shown at 32, the PCD type unit is in a detect mode, and makes a finding of an arrhythmia (VF/VT) following a charging period. Following this at Tl, the system sets up a confirm/sync interval 34, which is shown as being of predetermined duration, but which may in fact be of variable duration, as discussed further below. During the confirm/sync duration 34, the system seeks either to confirm the arrhythmia and to deliver a synchronized shock; or time out the interval without confirm~tion. In this simple illustration, looking for a normal sinus rhythm is not shown. The confirm/sync interval, illustrated as T2 - Tl has a duration corresponding to a predetermined brady escape interval, e.g., corresponding to apacing rate in the range of 60-120 bpm. When the confirm/sync escape interval runs out at T2, a ventricular pace pulse is delivered (instead of a shock). A capture interval is established, illustrated at 36, having a duration of about 200 ms and terrnin~ting at time T3. During this interval the system monitors a far field signal, such as between electrode 20 and the can 10, or between electrode 20 and SCV coil 30. If there is a signal sensed between these far field electrodes, and the signal correlates to the ventricular pacing stimulus, this indicates ventricular capture and is clear evidence of a bradycardia or asystole. This conclusion follows because only in such a circurnstance is there enough myocardial mass stimulated so as to produce a signal which can be detected as a far field signal, i.e., at electrodes displaced from the site where the pace pulse is delivered. Following capture, the system suitably m~int~in.~ a pacing mode. Conversely, if there is no correlation between the ventricular pacing stimulus and the far field signal during the capture duration, this is a certain indication of the presence of an undersensed ventricular allhylhl,lia. It is noted that in the case of VF/VT, the myocardial mass which can be st~ tçd is too small to produce a detectable far field signal, i.e., far field IECG. Under these circumstances, a shock of a~propl;ate power, depending upon the nature ofthe ~ulLyLlllllia is delivered at time T3.
Referring now to Fig. 2B, there is shown a timing diagram of a more specific illustrative embodiment. As was the case in Fig. 2A, fibrillation (or other ventricular allhyl~ia) is detected at time Tl. The confirm/sync duration, T 2- T l~ is structured to include plural intervals, namely a blanlcing interval (~L) which extends l 5 to a time Tb; a refractory interval (Ref) which extends through to time T r; a sync interval which follows Tr and extends to time Ts; and a "normal" interval which extends from Ts until T2. As presente~l, the timing diagram is illustrative, and the respective durations are not nçcess~nly drawn to scale. The entire duration from Tl to T2 constitutes a brady interval corresponding to a rate in the range of about 60-120 bpm. Any R wave which is sensed during the blanking duration is ignored. An R
wave sensed during the refractory interval may be utilized or not, depending upon the alg~ hLn chosen. Assuming that an R wave sensed before Tr is not used, the system then looks for the presence of an R wave during the sync interval. An R wave that is sensed during this sync period has come sufficiently rapidly that it is confiImed as an arrhythrnia, and a shock is delivered in sync with such sensed R wave. However, an R wave received after Ts but before T2 is deemed to be a normal beat and not to be an arrhythrnia, and no shock is delivered; since such a sensed R wave is an indication of a nonnal heartbeat, or a non-sustained ~hylh~llia, the ~lhyll~ulia is not confirmed, and the episode is t~rmin~t~l However, if no R wave has been detected by time T2, then a pace pulse is delivered at time T2. The pace pulse is suitably at m~il~llllll CA 0220709~ 1997-06-0~
available pacing output, to optimize the probability of capture. For a standard PCD
manufactured by Medtronic, Inc., this is an 8.4 volt pulse at 1.6 ms pulse width.
Following delivery of a pace pulse at T2, the system waits until time T3; it then either confirms capture, in which case the system reverts to a pacemaker mode of operation, or in the event of non-capture, delivers appropl;ate shock therapy.
Referring now to Fig. 2C, there is shown another timing diagram, illustrated in relation to the timing of Fig. 2B, to illustrate another exemplary embodiment where a first R wave is sensed during the refractory interval. In this embodiment, the first sensed R wave causes the establishment of a second confirm/sync interval. The difference in this embodiment is that an R wave detected - during the first refractory interval causes a second confirm/sync interval to be timed out, but without a refractory interval. This enables syncing on a second R wave if one is found within the second established interval. Failure to confirm results in delivery of a pace pulse at time T22, and delivery of a shock at time T33 if the pace pulse does not result in capture.
Referring now to Fig. 3, there is shown a block diagram illustrating the primary functional components of a PCD type appa.~us in accordance with this invention. It is to be understood that the functional blocks here illustrated may be established either with hardware, software, or a combination of haldw~ or software, as is well known in the art. A pace generator 41, which is controlled by pace control 42, produces pacing pulses which are connected between distal electrode 26 and either electrode 30 or can 10 for unipolar pacing (not shown); or, as shown, between electrodes 26 and 24 for bipolar pacing. Electrodes 26 and 24 are also connected to the input of pace/sense amplifier/processor 48, for bipolar sensing of ventricular signals. Although not shown, bipolar sensing may also be done between electrodes 24 and 20; and unipolar sensing can be done between electrode 26 and can 10. A
cardioverter/defibrillator generator 44, which is controlled by C/D control unit 45, provides an output illustrated as connected between RV coil 20 and SCV coil 30, or alternately between coil 20 and the pacemaker can 10. See referenced U.S. Patent5,188,105, for an illustration of C/D control and pulse generation. Sensed R wave signals are coupled at pace control 42, for norrnal control of pacing when the device is in a pacing mode. The sensed R wave signals are also connected to VF/VT detect block 52, for detection of the presence of an underlying VF/VT ~lhylhlllia. See U.S.
Patents Nos. 5,458,619 and 5,342,402 which disclose generally allhyLhll~ia detection as perforrned in a PCD type device. When VF/VT is detected, a signal is connected to block 54 to tirne out and control the confirm/sync period. This block contains the logic for carrying out the operations as set forth in the timing diagrams shown above. Thus, if the confirm/sync period times out without any R wave detection, a signal is passed to pace control 42, to cause delivery of a high level pace pulse. On the other hand, if an R wave is ~letecte~l which is ~etermined to be part of a sequence of VT or VF, a signal is sent to C/D control block 45, for c~ncing initiation of a C/D shock by generator 44. Control confirm/sync block 54 also ti_es out the following capture interval, and connects the timing signals to block 56. Block 56 is cormected to receive a far field sense signal from block 50, which signal will be recognized at block 56 during the interval from T2 to T3. Block 56 suitably employs a binary correlator, which takes advantage of the binary ~h~r~cter of signals and the fact that it can be implemente~l highly efflciently on a _icroprocessor. Such binary correlators are well known in the art.
In practice, in addition to the correlator/capture block 56 which is implemented with a microprocessor, the functions at blocks 52 and 54 are also preferably implemented with a microprocessor and a~lopliate software algolil~
control. The rem~inin~ blocks are normally implemented by hardware, although certainly portions of these functions, such as the pace control and C/D control may be impl.om~nte~l by software.
Referring now to Fig. 4, there is shown a logic diagram for carrying out the plilll~ y functions of this invention. At 60, a d~lr. ~ fion of VF/VT is made.
Following this, the PCD type unit is ~le~a~ed for delivery of a C/D shocl~, as shown at 62. The logic then initiates time out of the confirm~tion/sync duration, as illustrated at 63. At 64, it is deterrnined what, if anything, has happened during time out of the confirm~tion period. If allhyl~ia is confirmed and a shock is indicated, CA 0220709~ 1997-06-0~
the synced shock is delivered as shown at 66. If the brady escape interval has timed out, a pace pulse is delivered as illustrated at 68. At 70, it is determined whether there is an indication of capture resulting from the pace pulse, within the capture duration of around 200 ms. If yes, the shock delivery is disabled, as illustrated at 72, following which pacing may be maintained if appropriate. If no, meaning that the pace pulse did not capture the heart, this represents confirm~tion of the underlying arrhythmia, and the pacer applies a C/D pulse as illustrated at 74. Returning to block 64, if a normal sinus is detected, shock delivery is disabled.
There has thus been illustrated a PCD type system and method for accurately detennining the presence or absence of a maintained underlying arrhythmia, i.e., distinguishing VF/VT from marked bradycardia or asystole. By using defibrillator (far field) electrodes to sense whether an R wave occurs which correlates with the delivered pace pulse, the system very accurately distinguishes a brady situation from an undersensed arrhythmia. The use of a confirm/sync periodfollowing detection of VF/VT, and limiting such period to the equivalent of a brady escape interval, enables delivery of a synchronous shock, or an asynchronous VF/VT
shock when a~propliate and without undue delay, while also enabling a more appropriate pacing therapy where the arrhythmia has not been m~int~ined.
As used herein, the terms "shock," "shock pulse," and "anti-arrhythmia pulse" are used interchangeably, and refer to one or more coupled pulses delivered for defibrillation or cardioversion. The term "far field" is used as meaning sensing the R
wave between two electrodes displaced from the site where the pace pulse is delivered.
SYSTEM AND METHOD FOR DISTINGUISHING BETWEEN
VF/VT AND BRADYCARDIA OR ASYSTOLE
BACKGROUND OF THE INVENTION
This invention relates to a system and method for defibrillation and/or cardioversion and, more particularly, for safely determining whether or not a detected arrhythmia has been sustained, and for avoiding delivering of an inappropriate shock when in fact arrhythmia has not been sustained and the patient has marked bradycardia or asystole.
The implantable cardioverter defibrillator (ICD) device has been shown to be effective in termin~ting episodes of ventricular fibrillation (VF) and ventricular tachycardia (VT). This capacity for detecting and termin~ting potentially lethal ~lhyllllllias such as VF/VT has been further combined with the pacemaker function, the combined unit being referred to as a PCD (pacemaker/cardioverter/
defibrillator) type device, such as made by Medtronic, Inc., the assignee of this invention. The capability of this device has been further enhanced by the development of leads for providing transvenous ventricular defibrillation. See, for example, U.S. Patents Nos. 4,932,407 and 5,174,288, disclosing lead systems providing transvenous ventricular defibrillation and cardioversion electrodes.
Likewise, subcutaneous defibrillation leads may be used. The PCD or ICD type device, together with the improved leads, make it possible to provide relativelyefficient systems for termin~ting VT or VF.
A rem~ining problem with such systems for dealing with such dangerous arrhythmias is the potential for delivering an inappropliate shock. Inparticular, this invention addresses the problem where an arrhythmia such as VT or VF has been accurately sensed but has not been sustained. In such a situation, the detection of VT or VF results in the system being primed to deliver a shock. If,however, the patient exhibits either marked bradycardia or asystole when the device seeks confirm~tion of the previously detected allhyLlllllia, the lack of a sensed signal can be taken as confirm~tion of an underlying arrhythmia, resulting in an CA 0220709~ 1997-06-0~
p4350 ina~plopliate shock. The total number of inapl~ropl;ate shocks varies according to the literature, but remains significant enough to be regarded as a major challenge. In order to deal with this, ICD and PCD type devices have incorporated a variety ofreconfirm~tion algorithms, which are aimed at confirming the underlying arrhythmia after it has been detected, thereby reducing the number of inapplopliate shocks. Of course, the confirm~tion, or reconfirm~tion algorithm must take into account that failure to deliver a shock when a potentially lethal arrhythmia persists cannot be accepted; the arrhythmia confirrn~tion needs to be substantially 100 percent.
As an example of the above, in a typical PCD type device, there is a confirm~tion period following detection of, for example, a condition of fibrillation.
This confirrn~tion period serves two purposes. First, an attempt is made to deliver shock therapy synchronously with a patient heartbeat, when a sustained arrhythmia is sensed. For this reason, the system may look for one or two R waves that are consistent with the arrhythmia, and deliver a synchronous shock. However, if a predetermined confirm~tion period expires without any sensed signal, then a shock is delivered asychronously at the end of such period. This could likely be the correct result, where the absence of a sensed R wave is reflective of an underlying fibrillation or other arrhythmia. However, the time out of the confirm~tion period can also result from the patient having reverted to marked bradycardia or asystole after a non-sustained arrhythmia. It is clear that it is desirable to distinguish such a marked bradycardia or asystole, i.e., a non-sustained arrhythmia, from an undersensed real arrhythmia (VF/VT). The safe differentiation between a bradycardia episode and aVF/VT episode is desirable in order to provide delivery of a more appropriate pacing therapy instead of an inappropriate shock.
There thus is presented a significant need for improving the confirm~tion routine of a PCD or ICD type device, so as to avoid shock delivery during the confirm:~tion period in the event of a bradycardia condition (e.g., bradycardia or asystole) after a non-sustained arrhythmia, without sacrificing the sensitivity of arrhythmia detection and following therapy. It is also important, in either case, to deliver the most approp~;ate and most beneficial therapy without delay:
CA 0220709~ 1997-06-0~
in the case of bradycardia or asystole after a non-sustained arrhythmia, this isappropriate anti-bradycardia pacing, while in the case of the ventricular arrhythmia this constitutes prompt defibrillation or cardioversion therapy.
SUMMARY OF THE INVENTION
In accordance with the above need in the art, there is provided a system and method for detecting cardiac arrhythmias such as ventricular fibrillation ortachycardia, the system having the capability following such a detection for accurately distinguishing between a sustained arrhythmia requiring shock therapy and a non-sustained arrhythmia which is replaced by brady conditions of the sort for which only 1~ pacing therapy is desired. The system includes a PCD type unit and a suitable electrode system such as an endocardial lead with defib and pacing electrodes. The system continually senses cardiac signals and detects from such sensed signals an occurrence of VT/VF. Following this, the system enters a confirm~tion sequence where it seeks to deliver a shock in the event that sustained VF or VT is confirmed.
The confirm~tion sequence lasts for at least a predetermined brady interval, and if arrhythmia is not positively confirmed, or a normal sinus rhythm is not detected, a pace pulse is delivered at the time out of the confirm~tion interval. The system looks to determine whether the delivered pace pulse has captured the heart, preferably by ex~mining any signal sensed at the defibrillation far field electrodes, which sensed signal is indicative of heart capture. If capture is sensed within a predetermined interval following the pace pulse, then the system continues in a pacer mode, e.g., VVI pacing. However, if capture is not sensed, this verifies that the underlyingarrhythmia has been sustained and a shock is delivered at the time out of the predetermined interval following delivery of the pace pulse. The capture detection feature is "fail-safe" with respect to reacting to a dangerous therapy, since failure to detect capture results in delivery of a shock.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is an illustration of a PCD type system according to the present invention.
. . CA 02207095 1997-06-05 Fig. 2A is a simple timing diagram illustrating the operation of a PCD
type device embodying the present invention.
Figs. 2B and 2C are timing diagrams illustrating specific arrangements of the confinn~tion period and follow-up capture period in accordance with this invention.
Fig.3 is a block, functional diagram of a PCD type device adapted to carry out the co~ tion and capture fe~L~LLes of the present invention.
Fig. 4 is a flow diagram of the logic illustrating the method of the present invention for an episode of ventricular fibrillation.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Refemng now to Fig. 1, there are illustrated a defibrillator 10 and a lead 16, m~kin~ up the PCD type system of this invention. The lead shown is illustrative, it being noted that other specific forms of leads are within the scope of this invention. See, for example, the above-referenced U.S. Patents Nos. 4,932,407 and 5,174,288, as well as 5,261,400 . The - lead as illustrated has, located adjacent the distal end, an e~t~n~l~kle helix electrode 26 and a ring electrode 24, the helix electrode being mounted retractably within aninsulative head 28. Electrodes 24 and 26 are utilized for bipolar cardiac pacing and for sensing ventricular depol~ri7~tions. While electrodes 24, 26 may be used forbipolar pacing and sensing, electrode 26 may be used in conjunction with a surface of device can 10, which surface acts as a common or indirre;lellt electrode in what is termed unipolar operation. The lead also carries a coil electrode 20, sometimes referred to as the RV coil, for delivering defibrillation andlor cardioversion pulses.
Electrode 20 is positioned on the lead so that when the distal tip is at the apex of the ventricle, coil 20 is positioned in the right ventricle. Lead 16 may also carry,optionally, an SCV coil 30, positioned in the subclavian vein, which can be used for R
wave sensing and/or applying cardioversion pulses. Lead 16 carries respective concentric coil conductors, separated from one another by al~propl;ate means such as tubular insulative sheaths and running the length of the lead for m~kin~ electrical CA 0220709~ 1997-06-0 connection between the PCD device 10 and respective ones of electrodes 20, 24, 26 and 30.
An implantable PCD type device, or defibrillator 10, is shown in combination with the lead, with the lead connector assembly 14 being inserted into the connector block 12 of the device 10. A specific example of a defibrillation pulse generator which may be used in conjunction with the present lead, is disclosed in U.S.
Patent No. 4,953,551. Other PCD type units can be used; reference is made to U.S.
Patents 5,163,427 and 5,188,105 as disclosing illustrative forms of apparatus for delivering cardioversion and defibrillation pulses. As used herein, the term "PCD
type" device refers to any device which can apply both pacing therapy and shock therapy for controlling allhyll~ ias.
Referring now to Fig. 2A, there is shown a simple timing diagram, which illustrates the timing sequence and the primary operations of the present invention. As shown at 32, the PCD type unit is in a detect mode, and makes a finding of an arrhythmia (VF/VT) following a charging period. Following this at Tl, the system sets up a confirm/sync interval 34, which is shown as being of predetermined duration, but which may in fact be of variable duration, as discussed further below. During the confirm/sync duration 34, the system seeks either to confirm the arrhythmia and to deliver a synchronized shock; or time out the interval without confirm~tion. In this simple illustration, looking for a normal sinus rhythm is not shown. The confirm/sync interval, illustrated as T2 - Tl has a duration corresponding to a predetermined brady escape interval, e.g., corresponding to apacing rate in the range of 60-120 bpm. When the confirm/sync escape interval runs out at T2, a ventricular pace pulse is delivered (instead of a shock). A capture interval is established, illustrated at 36, having a duration of about 200 ms and terrnin~ting at time T3. During this interval the system monitors a far field signal, such as between electrode 20 and the can 10, or between electrode 20 and SCV coil 30. If there is a signal sensed between these far field electrodes, and the signal correlates to the ventricular pacing stimulus, this indicates ventricular capture and is clear evidence of a bradycardia or asystole. This conclusion follows because only in such a circurnstance is there enough myocardial mass stimulated so as to produce a signal which can be detected as a far field signal, i.e., at electrodes displaced from the site where the pace pulse is delivered. Following capture, the system suitably m~int~in.~ a pacing mode. Conversely, if there is no correlation between the ventricular pacing stimulus and the far field signal during the capture duration, this is a certain indication of the presence of an undersensed ventricular allhylhl,lia. It is noted that in the case of VF/VT, the myocardial mass which can be st~ tçd is too small to produce a detectable far field signal, i.e., far field IECG. Under these circumstances, a shock of a~propl;ate power, depending upon the nature ofthe ~ulLyLlllllia is delivered at time T3.
Referring now to Fig. 2B, there is shown a timing diagram of a more specific illustrative embodiment. As was the case in Fig. 2A, fibrillation (or other ventricular allhyl~ia) is detected at time Tl. The confirm/sync duration, T 2- T l~ is structured to include plural intervals, namely a blanlcing interval (~L) which extends l 5 to a time Tb; a refractory interval (Ref) which extends through to time T r; a sync interval which follows Tr and extends to time Ts; and a "normal" interval which extends from Ts until T2. As presente~l, the timing diagram is illustrative, and the respective durations are not nçcess~nly drawn to scale. The entire duration from Tl to T2 constitutes a brady interval corresponding to a rate in the range of about 60-120 bpm. Any R wave which is sensed during the blanking duration is ignored. An R
wave sensed during the refractory interval may be utilized or not, depending upon the alg~ hLn chosen. Assuming that an R wave sensed before Tr is not used, the system then looks for the presence of an R wave during the sync interval. An R wave that is sensed during this sync period has come sufficiently rapidly that it is confiImed as an arrhythrnia, and a shock is delivered in sync with such sensed R wave. However, an R wave received after Ts but before T2 is deemed to be a normal beat and not to be an arrhythrnia, and no shock is delivered; since such a sensed R wave is an indication of a nonnal heartbeat, or a non-sustained ~hylh~llia, the ~lhyll~ulia is not confirmed, and the episode is t~rmin~t~l However, if no R wave has been detected by time T2, then a pace pulse is delivered at time T2. The pace pulse is suitably at m~il~llllll CA 0220709~ 1997-06-0~
available pacing output, to optimize the probability of capture. For a standard PCD
manufactured by Medtronic, Inc., this is an 8.4 volt pulse at 1.6 ms pulse width.
Following delivery of a pace pulse at T2, the system waits until time T3; it then either confirms capture, in which case the system reverts to a pacemaker mode of operation, or in the event of non-capture, delivers appropl;ate shock therapy.
Referring now to Fig. 2C, there is shown another timing diagram, illustrated in relation to the timing of Fig. 2B, to illustrate another exemplary embodiment where a first R wave is sensed during the refractory interval. In this embodiment, the first sensed R wave causes the establishment of a second confirm/sync interval. The difference in this embodiment is that an R wave detected - during the first refractory interval causes a second confirm/sync interval to be timed out, but without a refractory interval. This enables syncing on a second R wave if one is found within the second established interval. Failure to confirm results in delivery of a pace pulse at time T22, and delivery of a shock at time T33 if the pace pulse does not result in capture.
Referring now to Fig. 3, there is shown a block diagram illustrating the primary functional components of a PCD type appa.~us in accordance with this invention. It is to be understood that the functional blocks here illustrated may be established either with hardware, software, or a combination of haldw~ or software, as is well known in the art. A pace generator 41, which is controlled by pace control 42, produces pacing pulses which are connected between distal electrode 26 and either electrode 30 or can 10 for unipolar pacing (not shown); or, as shown, between electrodes 26 and 24 for bipolar pacing. Electrodes 26 and 24 are also connected to the input of pace/sense amplifier/processor 48, for bipolar sensing of ventricular signals. Although not shown, bipolar sensing may also be done between electrodes 24 and 20; and unipolar sensing can be done between electrode 26 and can 10. A
cardioverter/defibrillator generator 44, which is controlled by C/D control unit 45, provides an output illustrated as connected between RV coil 20 and SCV coil 30, or alternately between coil 20 and the pacemaker can 10. See referenced U.S. Patent5,188,105, for an illustration of C/D control and pulse generation. Sensed R wave signals are coupled at pace control 42, for norrnal control of pacing when the device is in a pacing mode. The sensed R wave signals are also connected to VF/VT detect block 52, for detection of the presence of an underlying VF/VT ~lhylhlllia. See U.S.
Patents Nos. 5,458,619 and 5,342,402 which disclose generally allhyLhll~ia detection as perforrned in a PCD type device. When VF/VT is detected, a signal is connected to block 54 to tirne out and control the confirm/sync period. This block contains the logic for carrying out the operations as set forth in the timing diagrams shown above. Thus, if the confirm/sync period times out without any R wave detection, a signal is passed to pace control 42, to cause delivery of a high level pace pulse. On the other hand, if an R wave is ~letecte~l which is ~etermined to be part of a sequence of VT or VF, a signal is sent to C/D control block 45, for c~ncing initiation of a C/D shock by generator 44. Control confirm/sync block 54 also ti_es out the following capture interval, and connects the timing signals to block 56. Block 56 is cormected to receive a far field sense signal from block 50, which signal will be recognized at block 56 during the interval from T2 to T3. Block 56 suitably employs a binary correlator, which takes advantage of the binary ~h~r~cter of signals and the fact that it can be implemente~l highly efflciently on a _icroprocessor. Such binary correlators are well known in the art.
In practice, in addition to the correlator/capture block 56 which is implemented with a microprocessor, the functions at blocks 52 and 54 are also preferably implemented with a microprocessor and a~lopliate software algolil~
control. The rem~inin~ blocks are normally implemented by hardware, although certainly portions of these functions, such as the pace control and C/D control may be impl.om~nte~l by software.
Referring now to Fig. 4, there is shown a logic diagram for carrying out the plilll~ y functions of this invention. At 60, a d~lr. ~ fion of VF/VT is made.
Following this, the PCD type unit is ~le~a~ed for delivery of a C/D shocl~, as shown at 62. The logic then initiates time out of the confirm~tion/sync duration, as illustrated at 63. At 64, it is deterrnined what, if anything, has happened during time out of the confirm~tion period. If allhyl~ia is confirmed and a shock is indicated, CA 0220709~ 1997-06-0~
the synced shock is delivered as shown at 66. If the brady escape interval has timed out, a pace pulse is delivered as illustrated at 68. At 70, it is determined whether there is an indication of capture resulting from the pace pulse, within the capture duration of around 200 ms. If yes, the shock delivery is disabled, as illustrated at 72, following which pacing may be maintained if appropriate. If no, meaning that the pace pulse did not capture the heart, this represents confirm~tion of the underlying arrhythmia, and the pacer applies a C/D pulse as illustrated at 74. Returning to block 64, if a normal sinus is detected, shock delivery is disabled.
There has thus been illustrated a PCD type system and method for accurately detennining the presence or absence of a maintained underlying arrhythmia, i.e., distinguishing VF/VT from marked bradycardia or asystole. By using defibrillator (far field) electrodes to sense whether an R wave occurs which correlates with the delivered pace pulse, the system very accurately distinguishes a brady situation from an undersensed arrhythmia. The use of a confirm/sync periodfollowing detection of VF/VT, and limiting such period to the equivalent of a brady escape interval, enables delivery of a synchronous shock, or an asynchronous VF/VT
shock when a~propliate and without undue delay, while also enabling a more appropriate pacing therapy where the arrhythmia has not been m~int~ined.
As used herein, the terms "shock," "shock pulse," and "anti-arrhythmia pulse" are used interchangeably, and refer to one or more coupled pulses delivered for defibrillation or cardioversion. The term "far field" is used as meaning sensing the R
wave between two electrodes displaced from the site where the pace pulse is delivered.
Claims (14)
1. An implantable system for detecting and treating predetermined types of cardiac fibrillation and tachycardia occurring in a patient, comprising:
sensing means for sensing cardiac signals from said patient;
detecting means for detecting an occurrence of one of ventricular fibrillation or ventricular tachycardia based on said sensed cardiac signals;
confirm means for analyzing said sensed cardiac signals during a predetermined period following a detected fibrillation or tachycardia, said confirm means including timing means for timing out said period;
pace means for delivering a pace pulse upon the occurrence of a time out of said period without an intervening sensed cardiac signal;
capture means for determining whether said delivered pace pulse resulted in capture of the patient's heart; and shock means for delivering a shock treatment to said patient's heart when said capture means determines a lack of a said capture in response to a said delivered pace pulse.
sensing means for sensing cardiac signals from said patient;
detecting means for detecting an occurrence of one of ventricular fibrillation or ventricular tachycardia based on said sensed cardiac signals;
confirm means for analyzing said sensed cardiac signals during a predetermined period following a detected fibrillation or tachycardia, said confirm means including timing means for timing out said period;
pace means for delivering a pace pulse upon the occurrence of a time out of said period without an intervening sensed cardiac signal;
capture means for determining whether said delivered pace pulse resulted in capture of the patient's heart; and shock means for delivering a shock treatment to said patient's heart when said capture means determines a lack of a said capture in response to a said delivered pace pulse.
2. The system as described in claim 1, wherein said sensing means further comprises far field sensing means for sensing a far field response to a said delivered pace pulse, and wherein said capture means has correlation means for determining when a said far field response is correlated to a said delivered pace pulse.
3. The system as described in claim 2, wherein said shock means comprises shock electrode means for delivering said shock treatment, and said far field sensing means comprises means for analyzing cardiac signals sensed at saidshock electrode means.
4. The system as described in claim 3, comprising a transvenous lead, said lead comprising at least one pace electrode and at least one shock electrode, said lead also having respective conductors for connecting said electrodes to said pace means and said shock means.
5. The system as described in claim 1, wherein said timing means times out said period to have a duration corresponding to a bradycardia escape interval.
6. The system as described in claim 3, comprising a transvenous lead, and wherein said shock electrode means comprises at least one coil electrode on said lead in position for placement in a patient's right ventricle.
7. A system for detecting and treating cardiac arrhythmias such as ventricular fibrillation and ventricular tachycardia when they occur in a patient, said system comprising:
a PCD type device, said PCD type device having pace means for generating and delivering pace pulses, shock means for generating anti-arrhythmia shocks, and sensing means for sensing cardiac signals from said patient;
electrode means for providing a plurality of electrodes, one of said electrodes being a common electrode, one of said electrodes being a shock electrode for positioning within the patient's right ventricle, and one of said electrodes being a pacing electrode for positioning in proximity to the inner wall of said patient's right ventricle;
said PCD device having detecting means for detecting the occurrence of an arrhythmia, timing means for timing out at least a predetermined time duration following detection of a said arrhythmia, confirming means for positively confirming when a said arrhythmia is maintained during the timing out of said duration, and capture means operative when there is no confirmed arrhythmiaduring said duration for determining if the patient's heart is or is not captured by a pace pulse delivered from said pace means, and shock control means for controlling said shock means to deliver a said anti-arrhythmia shock only when a said arrhythmia is confirmed or when the patient's heart is not captured by a pace pulse.
a PCD type device, said PCD type device having pace means for generating and delivering pace pulses, shock means for generating anti-arrhythmia shocks, and sensing means for sensing cardiac signals from said patient;
electrode means for providing a plurality of electrodes, one of said electrodes being a common electrode, one of said electrodes being a shock electrode for positioning within the patient's right ventricle, and one of said electrodes being a pacing electrode for positioning in proximity to the inner wall of said patient's right ventricle;
said PCD device having detecting means for detecting the occurrence of an arrhythmia, timing means for timing out at least a predetermined time duration following detection of a said arrhythmia, confirming means for positively confirming when a said arrhythmia is maintained during the timing out of said duration, and capture means operative when there is no confirmed arrhythmiaduring said duration for determining if the patient's heart is or is not captured by a pace pulse delivered from said pace means, and shock control means for controlling said shock means to deliver a said anti-arrhythmia shock only when a said arrhythmia is confirmed or when the patient's heart is not captured by a pace pulse.
8. A system for detecting and treating VF/VT forms of cardiac arrhythmia in a patient, first means for determining the occurrence of a VF/VT form of arrhythmia, second means responsive to a said determining of an arrhythmia for determining when said arrhythmia is or is not maintained, said second means having (a) pace means for delivering a pace pulse to the patient's ventricle;
(b) timing means for timing out a capture interval of predetermined duration; and (c) sense means for sensing an electrical activity indicative of responsive ventricular contraction during said capture interval inresponse to said pace pulse, and therapy response means for delivering a shock pulse to said patient to treat said arrhythmia only when a said responsive ventricularcontraction is not sensed.
(b) timing means for timing out a capture interval of predetermined duration; and (c) sense means for sensing an electrical activity indicative of responsive ventricular contraction during said capture interval inresponse to said pace pulse, and therapy response means for delivering a shock pulse to said patient to treat said arrhythmia only when a said responsive ventricularcontraction is not sensed.
9. The system as described in claim 8, comprising a transvenous lead having at least one shock electrode for positioning in the patient's ventricle, at least one pacing electrode for positioning against the inner wall of said patient's ventricle, and at least a third electrode, and wherein said therapy response means is connected to deliver said shock pulse to said shock electrode and to said third electrode, and said sense means is connected to sense signals between said shockelectrode and said third electrode.
10. The system as described in claim 9, wherein shock electrode is a coil positioned on said lead so as to be placed in the patient's ventricle and said third electrode is a coil positioned on said lead so as to be placed in the patient's subclavian vein.
11. The system as described in claim 8, wherein said sense means comprises a ventricular coil electrode and a SCV electrode.
12. The system as described in claim 8 comprising a PCD type device housed in a can and a transvenous lead connected to said device, and wherein
13 said sense means comprises a ventricular coil electrode on said lead and a common electrode positioned on said can.
13. The system as described in claim 8, wherein said pace means comprises a pace electrode for delivering pace pulses to a pacing site on the inner wall of said patient's ventricle, and said sense means comprises a pair of electrodesdisplaced from said pacing site.
13. The system as described in claim 8, wherein said pace means comprises a pace electrode for delivering pace pulses to a pacing site on the inner wall of said patient's ventricle, and said sense means comprises a pair of electrodesdisplaced from said pacing site.
14. The system as described in claim 8, wherein said second means further comprises confirm means operative before delivery of a pace pulse, for confirming when a said VF/VT arrhythmia is maintained and for controlling said therapy response means to deliver a said shock pulse whenever a said VF/VT
arrhythmia is confirmed.
arrhythmia is confirmed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/673,444 | 1996-06-28 | ||
US08/673,444 US5766225A (en) | 1996-06-28 | 1996-06-28 | System and method for distinguishing between VF/VT bradycardia or asystole |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2207095A1 true CA2207095A1 (en) | 1997-12-28 |
Family
ID=24702682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002207095A Abandoned CA2207095A1 (en) | 1996-06-28 | 1997-06-05 | System and method for distinguishing between vf/vt and bradycardia or asystole |
Country Status (6)
Country | Link |
---|---|
US (1) | US5766225A (en) |
EP (1) | EP0815900B1 (en) |
JP (1) | JPH1057509A (en) |
AU (1) | AU717122B2 (en) |
CA (1) | CA2207095A1 (en) |
DE (1) | DE69731257T2 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7840264B1 (en) | 1996-08-19 | 2010-11-23 | Mr3 Medical, Llc | System and method for breaking reentry circuits by cooling cardiac tissue |
US7908003B1 (en) | 1996-08-19 | 2011-03-15 | Mr3 Medical Llc | System and method for treating ischemia by improving cardiac efficiency |
US5978707A (en) | 1997-04-30 | 1999-11-02 | Cardiac Pacemakers, Inc. | Apparatus and method for treating ventricular tachyarrhythmias |
DE19800697B4 (en) * | 1998-01-10 | 2009-04-02 | Biotronik Gmbh & Co. Kg | Single electrode probe, especially for implantable defibrillators |
US6101416A (en) * | 1998-07-29 | 2000-08-08 | Pacesetter, Inc. | System and method for atrial autocapture in single-chamber pacemaker modes using far-field detection |
US6434428B1 (en) * | 1998-07-29 | 2002-08-13 | Pacesetter, Inc. | System and method for optimizing far-field R-wave sensing by switching electrode polarity during atrial capture verification |
US6345201B1 (en) * | 1998-07-29 | 2002-02-05 | Pacesetter, Inc. | System and method for ventricular capture using far-field evoked response |
US6169921B1 (en) * | 1998-12-08 | 2001-01-02 | Cardiac Pacemakers, Inc. | Autocapture determination for an implantable cardioverter defibrillator |
US7512441B2 (en) * | 1998-12-08 | 2009-03-31 | Cardiac Pacemakers, Inc. | Autocapture pacing/sensing configuration |
US6312388B1 (en) * | 1999-03-12 | 2001-11-06 | Cardiac Pacemakers, Inc. | Method and system for verifying the integrity of normal sinus rhythm templates |
US6442426B1 (en) | 1999-12-01 | 2002-08-27 | Pacesetter, Inc. | Implantable ventricular cadioverter-defibrillator employing atrial pacing for preventing a trial fibrillation form ventricular cardioversion and defibrillation shocks |
US6615089B1 (en) * | 2000-03-31 | 2003-09-02 | Cardiac Pacemakers, Inc. | System and method for verifying capture in a multi-site pacemaker |
US6522914B1 (en) * | 2000-07-14 | 2003-02-18 | Cardiac Pacemakers, Inc. | Method and apparatuses for monitoring hemodynamic activities using an intracardiac impedance-derived parameter |
US7069070B2 (en) * | 2003-05-12 | 2006-06-27 | Cardiac Pacemakers, Inc. | Statistical method for assessing autonomic balance |
US7386344B2 (en) * | 2004-08-11 | 2008-06-10 | Cardiac Pacemakers, Inc. | Pacer with combined defibrillator tailored for bradycardia patients |
US6751502B2 (en) | 2001-03-14 | 2004-06-15 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system with defibrillation threshold prediction |
US6772008B2 (en) | 2001-09-28 | 2004-08-03 | Cardiac Pacemakers, Inc. | Method and apparatus for avoidance of phrenic nerve stimulation during cardiac pacing |
US6937901B2 (en) * | 2001-10-31 | 2005-08-30 | Cardiac Pacemakers, Inc. | Capture verification for cardiac resynchronization pacing optimization |
US20030191404A1 (en) * | 2002-04-08 | 2003-10-09 | Klein George J. | Method and apparatus for providing arrhythmia discrimination |
US7010344B2 (en) | 2002-04-26 | 2006-03-07 | Medtronic, Inc. | Method and apparatus for delaying a ventricular tachycardia therapy |
US7101339B2 (en) * | 2002-12-13 | 2006-09-05 | Cardiac Pacemakers, Inc. | Respiration signal measurement apparatus, systems, and methods |
US7181273B2 (en) * | 2003-04-18 | 2007-02-20 | Medtronic, Inc. | Tachycardia synchronization delays |
US7200440B2 (en) | 2003-07-02 | 2007-04-03 | Cardiac Pacemakers, Inc. | Cardiac cycle synchronized sampling of impedance signal |
US7392084B2 (en) | 2003-09-23 | 2008-06-24 | Cardiac Pacemakers, Inc. | Demand-based cardiac function therapy |
US7572226B2 (en) | 2003-10-28 | 2009-08-11 | Cardiac Pacemakers, Inc. | System and method for monitoring autonomic balance and physical activity |
US7212849B2 (en) * | 2004-10-28 | 2007-05-01 | Cardiac Pacemakers, Inc. | Methods and apparatuses for arrhythmia detection and classification using wireless ECG |
US9295852B1 (en) * | 2005-08-04 | 2016-03-29 | Pacesetter, Inc. | System and method for confirming heart arrhythmia |
US7761142B2 (en) * | 2006-03-29 | 2010-07-20 | Medtronic, Inc. | Method and apparatus for detecting arrhythmias in a medical device |
US7840265B2 (en) * | 2007-12-18 | 2010-11-23 | Cardiac Pacemakers, Inc. | Anti-tachyarrhythmia system with selectively activated detection enhancements |
US9415226B1 (en) | 2007-12-20 | 2016-08-16 | Pacesetter, Inc. | Method and apparatus with anodal capture monitoring |
US20100121396A1 (en) * | 2008-11-10 | 2010-05-13 | Pacesetter, Inc. | Enhanced hemodynamics through energy-efficient anodal pacing |
CA2766866A1 (en) | 2009-06-29 | 2011-01-20 | Cameron Health, Inc. | Adaptive confirmation of treatable arrhythmia in implantable cardiac stimulus devices |
US8126546B2 (en) * | 2009-06-30 | 2012-02-28 | Pacesetter, Inc. | Anodal excitation of tissue |
US10328266B2 (en) | 2012-05-31 | 2019-06-25 | Zoll Medical Corporation | External pacing device with discomfort management |
EP2854940B1 (en) | 2012-05-31 | 2022-07-06 | Zoll Medical Corporation | Medical monitoring and treatment device with external pacing |
US11097107B2 (en) | 2012-05-31 | 2021-08-24 | Zoll Medical Corporation | External pacing device with discomfort management |
EP2967404B1 (en) | 2013-03-11 | 2019-05-22 | Cameron Health, Inc. | Device implementing dual criteria for arrhythmia detection |
US9604065B2 (en) | 2013-08-30 | 2017-03-28 | Cardiac Pacemakers, Inc. | Unwanted stimulation detection during cardiac pacing |
US9533159B2 (en) | 2013-08-30 | 2017-01-03 | Cardiac Pacemakers, Inc. | Unwanted stimulation detection during cardiac pacing |
CN106068141B (en) | 2014-01-10 | 2019-05-14 | 心脏起搏器股份公司 | System and method for detecting cardiac arrhythmia |
US10449361B2 (en) | 2014-01-10 | 2019-10-22 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US10463866B2 (en) | 2014-07-11 | 2019-11-05 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
WO2016126613A1 (en) | 2015-02-06 | 2016-08-11 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
US10130824B2 (en) | 2016-04-28 | 2018-11-20 | Medtronic, Inc. | Asystole detection and response in an implantable cardioverter defibrillator |
US10758737B2 (en) | 2016-09-21 | 2020-09-01 | Cardiac Pacemakers, Inc. | Using sensor data from an intracardially implanted medical device to influence operation of an extracardially implantable cardioverter |
US11559241B2 (en) * | 2019-10-01 | 2023-01-24 | Pacesetter, Inc. | Methods and systems for reducing false declarations of arrhythmias |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4114628A (en) * | 1977-05-31 | 1978-09-19 | Rizk Nabil I | Demand pacemaker with self-adjusting threshold and defibrillating feature |
US4953551A (en) * | 1987-01-14 | 1990-09-04 | Medtronic, Inc. | Method of defibrillating a heart |
US4932407A (en) * | 1988-12-15 | 1990-06-12 | Medtronic, Inc. | Endocardial defibrillation electrode system |
US5188105A (en) * | 1990-11-14 | 1993-02-23 | Medtronic, Inc. | Apparatus and method for treating a tachyarrhythmia |
US5163427A (en) * | 1990-11-14 | 1992-11-17 | Medtronic, Inc. | Apparatus for delivering single and multiple cardioversion and defibrillation pulses |
US5174288A (en) * | 1990-11-30 | 1992-12-29 | Medtronic, Inc. | Method and apparatus for cardiac defibrillation |
US5193536A (en) * | 1990-12-20 | 1993-03-16 | Medtronic, Inc. | Paced cardioversion |
US5261400A (en) * | 1992-02-12 | 1993-11-16 | Medtronic, Inc. | Defibrillator employing transvenous and subcutaneous electrodes and method of use |
US5320643A (en) * | 1992-10-06 | 1994-06-14 | Medtronic, Inc. | Automatic cardiac capture restoration and threshold-seeking method and apparatus |
US5411530A (en) * | 1992-11-13 | 1995-05-02 | Akhtar; Masood | Sensing algorithm for anti-tachycardia devices using dual chamber sensing |
US5350401A (en) * | 1993-03-26 | 1994-09-27 | Siemens Pacesetter, Inc. | Implantable cardioverter/defibrillator device having means for determining and treating low amplitude ventricular fibrillation and method thereof |
US5411524A (en) * | 1993-11-02 | 1995-05-02 | Medtronic, Inc. | Method and apparatus for synchronization of atrial defibrillation pulses |
US5458619A (en) * | 1993-11-29 | 1995-10-17 | Medtronic, Inc. | Apparatus and method for treating a tachyarrhythmia |
US5500008A (en) * | 1994-03-29 | 1996-03-19 | Ventritex, Inc. | Method and apparatus for delivering defibrillation shocks with improved effectiveness |
-
1996
- 1996-06-28 US US08/673,444 patent/US5766225A/en not_active Expired - Lifetime
-
1997
- 1997-06-05 CA CA002207095A patent/CA2207095A1/en not_active Abandoned
- 1997-06-23 AU AU26209/97A patent/AU717122B2/en not_active Ceased
- 1997-06-25 DE DE69731257T patent/DE69731257T2/en not_active Expired - Lifetime
- 1997-06-25 EP EP97304500A patent/EP0815900B1/en not_active Expired - Lifetime
- 1997-06-26 JP JP9170533A patent/JPH1057509A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69731257T2 (en) | 2005-10-20 |
AU717122B2 (en) | 2000-03-16 |
EP0815900A3 (en) | 1999-12-29 |
AU2620997A (en) | 1998-01-15 |
US5766225A (en) | 1998-06-16 |
EP0815900A2 (en) | 1998-01-07 |
EP0815900B1 (en) | 2004-10-20 |
JPH1057509A (en) | 1998-03-03 |
DE69731257D1 (en) | 2004-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5766225A (en) | System and method for distinguishing between VF/VT bradycardia or asystole | |
US6539256B1 (en) | Method and apparatus for treating cardiac arrhythmia using electrogram features | |
US7200436B2 (en) | Implantable pulse generator and method having adjustable signal blanking | |
US6430449B1 (en) | Catheter for treating supraventricular tachyarrhythmias | |
US8412316B2 (en) | Atrial tachyarrhythmia detection system and method | |
US5558098A (en) | Method and apparatus for detecting lead sensing artifacts in cardiac electrograms | |
CA2318907C (en) | System for inducing tachycardia utilizing near field t-wave sensing | |
EP1064050B1 (en) | System for treating atrial arrhythmias | |
EP1110581A2 (en) | Implantable ventricular cardioverter/defribrillator employing atrial pacing for preventing atrial fibrillation from ventricular cardioversion and defibrillation shocks | |
EP0564395A2 (en) | Improved apparatus and method for reliably detecting a depolarization activation wave of the heart and atrial defibrillator utilizing same | |
US6195584B1 (en) | Method and apparatus for determining atrial lead dislocation | |
JPH08511717A (en) | Implantable cardioverter-defibrillator utilizing adaptive refractory period | |
US8214037B2 (en) | Implantable pulse generator and method having adjustable signal blanking | |
US20020082649A1 (en) | Safety pacing in multi-site CRM devices | |
US5899929A (en) | System for inducing tachycardia utilizing near field T-wave sensing | |
WO1998053879A1 (en) | System and method for ventricular defibrillation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |